Status: Recruiting
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.
Participants needed: 324
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Mayo ClinicUpdated: Mar 12, 2026Locations: 3
Eligibility criteria
Lung: Non-small Cell Lung Cancer (NSCLC) [+29]
Pregnant women because this study involves a greater than minimal risk procedure... [+6]